AzTrials
AzTrials

Glucose ControlNCT07433049

Impact of Supplementation in Improving Metabolic Health Outcomes (ISMOS) Study

A study testing Multivitamin/mineral study product in people with Glucose Control and Mental Health, run by Institute for Human Development and Potential (IHDP), Singapore at 1 site in Singapore.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study investigates the role of multivitamin and multimineral (MVM) supplementation in improving metabolic, musculoskeletal, and mental health among midlife Asian women aged 40-60 years, a critical period marked by hormonal and physiological transitions from pre- to post-menopause. Read more about this study

Who is it for?
Ages 40 to 60 years, women onlyHealthy volunteers can take part
What is being tested?
Multivitamin/mineral study product
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
400 participants
Where
1 siteSingapore
Study dates
20 Jan 2026to Jan 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 60 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Women aged 40-60 years old
  • Chinese, Malay or Indian
  • BMI between 23.0-35.0 kg/m2
  • Proficient in English language
  • Willing to comply with study protocol \& provide informed consent

Who cannot join

  • Pregnant or planning a pregnancy
  • Diagnosis with Diabetes, Polycystic Ovary Syndrome (PCOS), autoimmune diseases, chronic organ failure, severe heart disease, eating disorders and/or other medical conditions which in the PI's judgment which may affect study outcomes
  • Fasting glucose value ≥ 7.0 mmol/L
  • Active cancer or treatment of cancer in the last 3 years
  • Participating in other nutritional intervention studies
  • Taking oral corticosteroids, anti-psychotic and/or weight loss drugs
Show all 10Show fewer
  • Having planned hospitalization in the next 12 months
  • Planning to have major diet changes in the next 12 months
  • Taking a medically prescribed supplement(s) that contains 3 or more of the ingredients of the study product
  • Taking a non-prescribed supplement(s) that contains 3 or more of the ingredients of the study product in the last 1 month

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Johan Eriksson, MD contact

80616604

johan_eriksson@a-star.edu.sg

Mya Thway Tint, PhD contact

mya_thway_tint@a-star.edu.sg

Singapore1 site, 1 recruiting
  • Institute for Human Development and Potential (IHDP)

    Singapore, 117597

    Jolene Chee, jolene_chee@a-star.edu.sg

    Recruiting

Other trials in Singapore

About this study

This study investigates the role of multivitamin and multimineral (MVM) supplementation in improving metabolic, musculoskeletal, and mental health among midlife Asian women aged 40-60 years, a critical period marked by hormonal and physiological transitions from pre- to post-menopause. Evidence from the GUSTO cohort in Singapore has shown that higher plasma levels of vitamins B6, B9, B12, and D are associated with better metabolic profiles, insulin sensitivity, and mental wellbeing, while deficiencies are linked to increased metabolic and psychological risks. Given that vitamin insufficiency and central obesity are highly prevalent among Asian women even at lower BMI, this randomized, double-blind, placebo-controlled trial will evaluate whether 12 months of daily MVM supplementation can reduce MetaboAge and improve metabolic, mental, and muscle health outcomes compared with placebo. Findings will inform preventive strategies for extending health span and mitigating chronic disease risks among midlife women in Asia.

Read the detailed description

Vitamins are essential micronutrients that regulate key metabolic pathways involved in energy metabolism, immune function, and neuronal integrity. Adequate vitamin status is critical during midlife (ages 40-60 years), a period marked by hormonal fluctuations and physiological transitions from pre- to peri- and post-menopause. These transitions profoundly affect women's metabolic, musculoskeletal, and mental health trajectories, often predisposing them to metabolic syndrome, insulin resistance, central adiposity, dyslipidaemia, and hypertension. Concurrently, declines in muscle strength, bone mineral density, and mood are frequently observed, heightening the risk of sarcopenia, osteopenia, and depressive symptoms in later life.

Emerging evidence indicates that suboptimal dietary intake or deficiency of vitamins contributes to these adverse outcomes. Vitamin D insufficiency, highly prevalent in Asia, has been linked to metabolic syndrome, insulin resistance, and mood disturbances in postmenopausal women. Similarly, low levels of B-vitamins, vitamin C, vitamin E, and folate have been associated with impaired glucose regulation, higher inflammatory burden, and poorer muscle function. While several studies in Western populations have reported positive correlations between these micronutrients and musculoskeletal or psychological health, corresponding data in Asian women remain limited despite their higher susceptibility to central obesity and metabolic dysfunction at lower BMI thresholds compared to Western populations.

Findings from the Growing Up in Singapore Towards Healthy Outcomes (GUSTO) cohort provide novel insights into the role of vitamin status in Asian women. Plasma concentrations of vitamins B6, B9, B12, and D were associated with favorable metabolic profiles, including lower metabolic syndrome severity, improved insulin sensitivity, reduced HbA1c, and higher HDL-cholesterol. Furthermore, higher thiamine monophosphate (vitamin B1) levels correlated with greater handgrip strength, while elevated folate was inversely related to depressive symptoms and perceived stress. Importantly, these associations were more pronounced among women with a BMI ≥ 23 kg/m², emphasizing the compounded metabolic vulnerability of overweight Asian phenotypes. Collectively, these findings highlight the potential of multivitamin/multimineral (MVM) supplementation as a preventive strategy to mitigate age-related metabolic, musculoskeletal, and psychological decline during midlife.

Building on these observational findings, this randomized, double-blind, placebo-controlled trial aims to determine whether 12 months of daily MVM supplementation can improve metabolic and overall health in relatively healthy middle-aged Asian women. The trial will recruit women aged 40-60 years, a critical window for metabolic and hormonal adaptation, who are at increased risk of vitamin insufficiency, insulin resistance, and low-grade chronic inflammation. Participants will be randomized to receive either a daily MVM supplement or placebo for one year, with comprehensive assessments at baseline, 6 months, and 12 months.

The investigators hypothesize that daily MVM supplementation for 12 months will reduce MetaboAge, a composite biomarker of metabolic aging and enhance metabolic, musculoskeletal, and mental health outcomes in midlife women compared with placebo.

Primary Objective is to examine the effect of 12-month MVM supplementation on MetaboAge among relatively healthy middle-aged Asian women.

Secondary Objectives are to;

  1. Evaluate the impact of MVM supplementation versus placebo on metabolic markers (fasting glucose, insulin resistance indices, HbA1c, lipid profile, blood pressure); mental health outcomes (depressive symptoms, perceived stress, quality of life); musculoskeletal health (lean mass, fat mass distribution, bone mineral density, and handgrip strength) and circulating micronutrient and inflammatory marker levels.
  2. To explore how menopausal status, baseline vitamin status, and body composition modify the observed intervention effects.

Scientific and Public Health Significance This trial is among the first in Asia to integrate multivitamin supplementation with multidimensional health outcomes; metabolic, musculoskeletal, and psychological, within the context of midlife transition. Asians are metabolically predisposed to visceral adiposity and insulin resistance even at lower BMI, placing midlife women at particularly high risk for metabolic syndrome and its sequelae. By addressing micronutrient insufficiency through a low-cost, scalable nutritional approach, this study aims to establish evidence for early preventive strategies that can extend functional health span and reduce the burden of chronic diseases among Asian women.

If proven effective, findings from this trial will support the incorporation of multivitamin supplementation or vitamin status screening into midlife health programs and community-based preventive frameworks, aligning with regional and national goals for promoting healthy longevity and metabolic resilience across the lifespan.

Being tested
Multivitamin/mineral study product
Keywords
Multivitamin and mineral supplementation, Women, Metabolic health, Mental health, Muscle health
Medical subject headings
Psychological Well-Being

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Multivitamin/mineral study productDietary supplement

    Participants will be randomised into one of the two study treatment arms

Study groups in NCT07433049
Study groupRoleWhat they receive
Multivitamin/mineral (MVM) study productExperimentalOne MVM study product to be taken once a day for 52 weeks
Receives: Dietary Supplement: Multivitamin/mineral study product
Placebo study productPlacebo comparatorOne placebo study product to be taken once a day for 52 weeks
Receives: Dietary Supplement: Multivitamin/mineral study product

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Changes in MetaboAge

    MetaboAge is a composite biomarker of metabolic aging derived from proton nuclear magnetic resonance (^1H-NMR) metabolomics profiling of serum samples. It reflects overall metabolic health and correlates with cardiometabolic risk and insulin sensitivity. The expected outcome is that daily multivitamin/multimineral (MVM) supplementation for 12 months will result in a reduction in MetaboAge compared with placebo, indicating improved metabolic profile and slower metabolic aging. The change in MetaboAge will be calculated as the difference between post-intervention and baseline values. A negative change in MetaboAge represents metabolic rejuvenation or improvement in metabolic health status.

    Measured: Changes in MetaboAge over one year, including: Week 0 (Baseline), Week 26 (Midpoint) and Week 52 (Endpoint)

Secondary outcomes (13)
  1. Anthropometric Measurements

    Participants will be measured for their height in m and weight in kg. Height and weight will be combined to report BMI in kg/m^2.

    Measured: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)

  2. Blood Pressure Measurements

    Blood pressure will be measured using an automated blood pressure monitor.

    Measured: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)

  3. Body Composition Assessment

    Body composition will be assessed using multi-frequency bioelectrical impedance analysis (BIA) with the InBody 970 (InBody Co., Seoul, Korea). Participants will be measured in a standing position using an 8-point tactile electrode system (hands and feet), and impedance will be recorded across multiple frequencies to estimate total and segmental lean mass, fat mass, and body fat percentage.

    Measured: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)

  4. 36-Item Short Form Survey (SF-36)

    Health-related quality of life will be assessed using the 36-Item Short Form Survey (SF-36), a validated instrument measuring eight domains of physical and mental wellbeing: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. Each domain score and the overall physical and mental component summary scores will be calculated according to standardized scoring procedures.

    The expected outcome is that 12 months of daily multivitamin/multimineral (MVM) supplementation will lead to improvement in SF-36 scores compared with placebo, reflecting better perceived physical and mental wellbeing during the midlife transition. The change from baseline (ΔSF-36) will be computed for total and domain-specific scores, with higher positive values indicating improved quality of life.

    Measured: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)

  5. Menopausal Status

    Menopausal Rating Scale (MRS)

    Measured: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)

  6. Anxiety

    State-Trait Anxiety Inventory (STAI)

    Measured: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)

  7. Depression

    Beck Depression Inventory (BDI)

    Measured: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)

  8. Stress

    Perceived Stress Scale (PSS)

    Measured: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)

  9. Sleep Quality

    Pittsburgh Sleep Quality Index (PSQI)

    Measured: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)

  10. Physical Activity

    International Physical Activity Questionnaire (IPAQ)

    Measured: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)

  11. Dietary Intake

    Food Frequency Questionnaire (FFQ)

    Measured: Week 0 (Baseline), Week 52 (Endpoint)

  12. Musculoskeletal assessment by peripheral quantitative CT (pQCT)

    Bone mineral density and muscle quality of lower limb (Tibia) will be measured using pQCT and measurement of the non-dominant tibia will be performed using Stratec XCT-3000. Single axial scans will be acquired at 4% and 66% of tibial length, expressed as a percentage from the distal reference line, to assess bone and lower-limb muscle.

    Bone parameters are derived using manufacturer software with standard contouring and density thresholds to segment total and trabecular compartments at 4% and cortical bone at 66%, generating measures such as total/trabecular volumetric BMD (vBMD), cortical vBMD, cortical thickness, cross-sectional area, and strength indices. At the 66% site, soft-tissue segmentation is additionally performed to quantify calf muscle cross-sectional area (CSA), muscle density, and subcutaneous/intermuscular fat CSA, using predefined attenuation thresholds to separate muscle from adipose tissue.

    Measured: From enrollment to the end of 12 months multi-vitamin supplementation.

  13. Physical performance assessment

    Physical performance will be assessed using a standardized physical performance battery that includes tests of handgrip strength, gait speed (4-meter walk test), chair stand test, and balance test. Composite physical performance scores will be derived according to established protocols, with higher scores reflecting better functional capacity and musculoskeletal health.

    The expected outcome is that 12 months of daily multivitamin/multimineral (MVM) supplementation will lead to improvements or maintenance of physical performance scores compared with placebo, indicating enhanced muscle strength, endurance, and coordination during the midlife transition. The change from baseline will be calculated for each test and the composite score, with positive values representing improved physical function.

    Measured: From enrollment to end of 12 months multi-vitamin supplementation

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Feb 2026
  2. Study start20 Jan 2026
  3. Primary completionJan 2028 (estimated)
  4. Study completionJan 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
A single center, prospective, double-blind, placebo-controlled Randomised Control Trial. Eligible women will be randomised at baseline to either intervention or control group. Participants will receive the assigned intervention from baseline to week 52.
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
400 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07433049
Sponsor's protocol ID
2025-064
Status last verified
Feb 2026
First submitted
22 Dec 2025
Last updated
25 Feb 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Multivitamin/mineral study product in people with Glucose Control and Mental Health, run by Institute for Human Development and Potential (IHDP), Singapore at 1 site in Singapore.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 25 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Johan Eriksson, MD (80616604, johan_eriksson@a-star.edu.sg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Changes in MetaboAge (time frame: Changes in MetaboAge over one year, including: Week 0 (Baseline), Week 26 (Midpoint) and Week 52 (Endpoint)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Feb 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in